Non-Clinical Drug Development

Non-clinical (preclinical) drug development involves laboratory and animal studies conducted to assess a drug’s safety, pharmacology, and pharmacokinetics before human trials.

Pharmacology Studies
- Primary Pharmacodynamics: Assess therapeutic effects on intended target.
- Secondary Pharmacodynamics: Investigate effects unrelated to therapeutic target.
- Safety Pharmacology: Evaluate adverse effects on vital systems (cardiovascular, respiratory, CNS).
Pharmacokinetics (PK) and ADME Studies
- Absorption: Entry into circulation.
- Distribution: Dispersion throughout the body.
- Metabolism: Chemical alterations in the body.
- Excretion: Elimination of drug and metabolites.
Toxicology Studies
- Acute Toxicity: Effects after a single dose.
- Subacute/Subchronic Toxicity: Effects after repeated dosing over short-to-medium durations.
- Chronic Toxicity: Long-term exposure effects.
- Genotoxicity, Carcinogenicity, Reproductive Toxicity, Immunotoxicity: Assess potential genetic, cancerous, reproductive, and immune effects.
In Vitro Studies
- Cell-based Assays and Receptor Binding: Test effects on cells and receptor interactions.
Animal Models
- Species Selection: Rodents and non-rodents.
- Dose and Study Design: GLP-compliant studies with ethically determined doses.

Good Laboratory Practice (GLP): Ensures data quality.
ICH Guidelines: International standards for non-clinical studies (e.g., ICH M3(R2)).

Safety Assessment: Identify toxicities and establish safe starting doses.
Efficacy Prediction: Show pharmacological activity supporting therapeutic potential.
Regulatory Compliance: Provide data for regulatory submissions (e.g., IND application).

Non-clinical studies form a critical foundation for assessing a drug’s safety and potential efficacy prior to human trials.